All Posts
U.S. Tariffs and Pharmaceutical Supply Chains in 2026
Navigate U.S. tariffs and pharmaceutical supply chains in 2026 — Section 232, IEEPA, USMCA, MFN
February 23, 2026
Navigate U.S. tariffs and pharmaceutical supply chains in 2026 — Section 232, IEEPA, USMCA, MFN
Analytical Development vs Process Development: Integrated CMC Strategy Across Drug Development Phases In pharmaceutical and
New York City in March is a study in contrasts. Outside, the weather oscillates between
Engineering Confidence in CMC Development—Let’s Connect in New York City DES Pharma (Dynamic Engineering Solutions)
Developing a therapeutic from lab to commercial launch requires much more than scientific innovation. it
Pharmaceutical quality assurance continues its evolution toward data-driven decision-making, process analytical technology, and risk-based validation
Executive Summary: Defining the New Bio Pharma Supply Chain Strategy The pharmaceutical supply chain in
In many industries, a manufacturing defect means a returned product and a frustrated customer. In
If the pharmaceutical landscape of 2025 was defined by resilience, 2026 is defined
Intro to Pharma Consulting: The Guide Behind the Science When most people think of the
Start building reliable, high-quality drug development programs today.